CSL Limited stock ends flat-ish near A$173 as February results loom

CSL Ltd closed Wednesday just 0.1% higher at A$173.49, after swinging between A$172.14 and A$174.69 during the session. Trading volume hit roughly 1.11 million shares. The stock has dropped roughly 37% over the last year, lingering just above its 52-week low of A$168.

ASX:CSL · Earnings Reports · Stock Market
CSL Limited (ASX:CSL) Stock Update on 24 December 2025: Share Price Drops, Buyback Progress, Seqirus Uncertainty, and 2026 Analyst Forecasts

CSL Limited (ASX:CSL) Stock Update on 24 December 2025: Share Price Drops, Buyback Progress, Seqirus Uncertainty, and 2026 Analyst Forecasts

That finish matters for two reasons. First, it keeps CSL hovering close to its 52‑week low after a bruising year for one of Australia’s most widely held “quality compounder” names. Investing.com Second, it lands amid a wider re‑rating story investors have been living through since August: CSL is no longer being priced like a smooth, predictable growth machine—markets are treating it like a business in the middle of a complicated reset.
24 December 2025
·
Australia Stock Market Today: ASX 200 Rises as Miners, Energy and Record Gold Lift Shares (22 December 2025)

Australia Stock Market Today: ASX 200 Rises as Miners, Energy and Record Gold Lift Shares (22 December 2025)

Australia’s sharemarket kicked off the pre-Christmas week in upbeat fashion on Monday, with the S&P/ASX 200 trading higher into the afternoon as miners and energy stocks led broad-based gains. By early afternoon in Sydney, the benchmark was up about 0.9% around 8,701 points, with most sectors in the green and risk appetite supported by stronger global leads and a fresh surge in commodities. ABC+1
22 December 2025
········
CSL Limited Stock (ASX: CSL) Outlook on 21 December 2025: Seqirus Spin-Off Delay, Buyback Momentum, and Analyst Price Targets

CSL Limited Stock (ASX: CSL) Outlook on 21 December 2025: Seqirus Spin-Off Delay, Buyback Momentum, and Analyst Price Targets

CSL Limited heads into the final stretch of 2025 with its share price still under pressure—but with a growing stack of “things that matter” piling up beneath the surface: a sizeable on‑market buyback steadily absorbing stock, a major US manufacturing investment designed to reinforce its plasma-therapy moat, and a high-profile strategic reset that’s trying to simplify a complex, three‑engine biotech into something the market can price with less guesswork.
21 December 2025
·
CSL Limited Stock (ASX:CSL): Latest News, Buyback Update, Analyst Price Targets and 2026 Outlook (20 Dec 2025)

CSL Limited Stock (ASX:CSL): Latest News, Buyback Update, Analyst Price Targets and 2026 Outlook (20 Dec 2025)

CSL Limited has spent 2025 reminding the market of an awkward truth: even “defensive” healthcare giants can deliver very non-defensive share price swings. After a year dominated by vaccine-market volatility, a reshaped strategy for CSL Seqirus, and investor nerves around China pricing, the stock heads into late December with a familiar question hanging in the air—is CSL Limited stock a bruised blue-chip bargain, or a business still working through its hardest chapter? TradingView+1
20 December 2025
CSL Limited Stock (ASX: CSL): Buyback Update, Analyst Forecasts, and the Key Catalysts Shaping the CSL Share Price on 18 December 2025

CSL Limited Stock (ASX: CSL): Buyback Update, Analyst Forecasts, and the Key Catalysts Shaping the CSL Share Price on 18 December 2025

CSL Limited spent much of 2025 reminding investors of a brutal truth: even world-class biopharma franchises can get whacked when costs, policy, and sentiment all lean the wrong way at the same time. On 18 December 2025, the CSL share price was A$174.57, up 0.68% on the day after trading between A$171.64 and A$174.65. Intelligent Investor
18 December 2025
·
CSL Limited Stock (ASX:CSL) Today: Buyback Update, Macquarie Downgrade, and What Analysts Forecast for 2026 (Dec 17, 2025)

CSL Limited Stock (ASX:CSL) Today: Buyback Update, Macquarie Downgrade, and What Analysts Forecast for 2026 (Dec 17, 2025)

CSL Limited shares ended Wednesday, December 17, 2025 lower as investors digested a fresh on-market buyback update and the lingering impact of broker downgrades that have reshaped sentiment around one of Australia’s most widely held healthcare names. CSL closed at A$172.77, down 2.47% on the day, after trading between A$172.75 and A$176.83 with roughly 800,720 shares changing hands. Investing.com
17 December 2025
CSL Limited Stock (ASX: CSL) Sinks on Macquarie Downgrade: Today’s News, Analyst Forecasts, and the 2026 Catalysts Investors Are Watching

CSL Limited Stock (ASX: CSL) Sinks on Macquarie Downgrade: Today’s News, Analyst Forecasts, and the 2026 Catalysts Investors Are Watching

CSL Limited is back in the spotlight on Monday, 15 December 2025 — and not for the reasons long-term holders are used to. After years of being treated as the ASX’s “defensive growth” heavyweight, CSL stock is now trading around the A$180 level, with investors weighing fresh broker caution against a still-solid consensus view that the shares are undervalued. Investing.com+1
15 December 2025
·
CSL Limited Stock (ASX:CSL) Update: Hemgenix 5-Year Data, Vaccine Audit Fallout, Buyback Support — Week Ahead Outlook (Updated 14 Dec 2025)

CSL Limited Stock (ASX:CSL) Update: Hemgenix 5-Year Data, Vaccine Audit Fallout, Buyback Support — Week Ahead Outlook (Updated 14 Dec 2025)

CSL Limited shares closed Friday at A$183.93, ending a volatile week only slightly lower overall after a sharp rebound into the weekend. Investors are weighing two very different storylines at once: encouraging long-term clinical data for CSL’s hemophilia B gene therapy HEMGENIX, and fresh scrutiny on Australia’s onshore vaccine manufacturing deals tied to CSL Seqirus — all while CSL continues to steadily mop up stock through its A$750 million on-market buyback. Global Newsroom | CSL+4Yahoo Finance+4Intelligent Investor+4
14 December 2025
··
CSL Limited Stock (ASX:CSL) After the Bell on Dec. 12, 2025: Buyback Update, HEMGENIX Five‑Year Data, Analyst Forecasts, and What to Watch Before the Next Open

CSL Limited Stock (ASX:CSL) After the Bell on Dec. 12, 2025: Buyback Update, HEMGENIX Five‑Year Data, Analyst Forecasts, and What to Watch Before the Next Open

CSL Limited shares finished Friday’s session firmly higher, with the biotech giant benefiting from a broader rebound in Australian healthcare stocks and fresh attention on two CSL-specific threads: its ongoing on-market share buyback and the latest long-term durability data for its hemophilia B gene therapy, HEMGENIX. Market Index+2CSL Limited+2
13 December 2025
··
1 2 3 4 5
Follow on Google News
Add as preferred source Open in Google News